- Harvoni & Sovaldi, Xtandi in Top 20 Costliest Medicare Drugs
- Letter from 56 non-profits and experts to Secretary of State John Kerry on pressure on global access to medicines initiatives
- Francis Gurry appoints Sylvie Forbin, lobbyist for Vivendi, as new head of copyright at WIPO
- WIPO Marrakesh Treaty for the blind to come into force September 30, 2016, following ratification by Canada
- Human Rights Council adopts watershed resolution on Access to Medicines
- SCP 24 - A fruitful discussion?
- SCP24: African Group submits revised proposal for a WIPO work program on Patents and Health
- SCP24: KEI statement on Patents and Health
- Briefing Call on National Institutes of Health (NIH) patent policies, 29 June 2016, 11:00 A.M. (EST)
- SCP24: KEI statement on exceptions and limitations to patent rights
2016: KEI/MSF comments to NIH on licensing of patents on Attenuated Respiratory Syncytial Virus (RSV) VaccinesSubmitted by James Love on 9. March 2016 - 8:04
Other KEI comments on NIH licenses can be found here: http://keionline.org/nih-licenses
On Monday, March 7, 2016, Congressman Lloyd Doggett, D-Texas, issued a statement in support of the recent Knowledge Ecology International (KEI) and Union for Affordable Cancer Treatment (UACT) request that the National Institutes of Health (NIH) authorize the generic production of an expensive prostate cancer drug in order to curb an excessive and discriminatory price in the United States.
TRIPS Council March 2016: India reiterates support for de-linkage and references UN High Level Panel on Access to MedicinesSubmitted by thiru on 7. March 2016 - 10:27
In early March 2016, the World Trade Organization's (WTO) TRIPS Council discussed "Intellectual Property and Innovation: Education and Diffusion". The following delegations co-sponsored discussion of this item on Education and Diffusion - Australia, European Union, Switzerland, United States, Japan, Singapore, Peru, Russian Federation, Chinese Taipei and Hong Kong China.
This is a slightly expanded version of the testimony we provided at the March 1, 2016 USTR Special 301 hearing. I had some trouble uploading to Regulations.Gov, but emailed a copy to Christine R. Peterson, the Director for Intellectual Property and Innovation. One addition was this data:
We sent this brief note to the Army today regarding this federal register note: https://federalregister.gov/a/2016-04494
From: Jamie Love
Date: Sat, Mar 5, 2016
Subject: Digital Optical Method patents
I am writing about the notice of intent for an exclusive license to patents on the Digital Optical Method (DOMTM ), United States Patent No. 7,495,767.
On March 4, 2016, KEI provided comments to the US Senate Committee on Finance on a report prepared by staff for Senators Grassley and Wyden that was issued by the committee on December 2015, titled “The Price of Sovaldi and Its Impact on the U.S. Health Care System.” Senators Grassley and Wyden asked the public to comment on various issues raised in the report. The comments we filed on March 4 included three major sections.
On March 3, 2016, KEI filed a comment with the U.S. Copyright Office in Docket No. 2015-8, regarding 17 U.S.C. § 1201.
The comment made specific recommendations regarding changes to the rulemaking procedure, the anti-trafficking provisions, and permanent exemptions, and also suggested requiring a registration and application process, as well as payment of a fee, for the DRM/TPM seeking legal protection under the law.
11 February 2016: 5 groups express concerns over WIPO statements relating to UN High-Level Panel on Access to MedicinesSubmitted by thiru on 4. March 2016 - 5:10
On Thursday, 11 February 2016, five groups including Knowledge Ecology International (KEI), Oxfam, Stop AIDS, Third World Network (TWN) and Treatment Action Campaign (TAC) sent a letter to Dr. Francis Gurry, Director-General of the World Intellectual Property Organization (WIPO) highlighting our concerns with statements expressed by WIPO relating to the United Nations Secretary General’s High-Level Panel on Access to Medicines (HLP). To date, we have yet to hear any formal response from WIPO.
(More on Colombia here: http://keionline.org/colombia)
Andrea Carolina Reyes Rojas informs us that a committee appointed to consider a request for a compulsory license on the leukemia drug Imatinib has decided that there are public interest reasons to do so.
Colombia Technical Committee Recommends Declaration that a Compulsory License on Imatinib (Gleevec) Would Be in Public InterestSubmitted by Andrew Goldman on 3. March 2016 - 13:46
(More on Colombia here: http://keionline.org/colombia)
In Colombia, a technical committee has issued a recommendation that a declaration be made that a compulsory license on imatinib (Gleevec) would be in the public interest. Under Colombian law, this is an important intermediary step prior to the actual grant of a compulsory license.
Attached below are the four submissions for which KEI was the lead author to the UN Secretary General's High Level Panel (HLP) on Access to Medicine.
- "The Need for Global Negotiations on Agreements to Fund R&D within the Context of a Progressive De-linking of R&D Costs from Product Prices". Supported by 12 organizations; 1 individual; 3 Members of European Parliament.
- "Increasing the Transparency of Markets for Drugs, Vaccines, Diagnostics and other Medical Technologies". Supported by 17 organizations; 2 individuals; 3 Members of European Parliament.
DHHS has declared a public health emergency over the Zika viru, and authorized emergency use of diagnostic tests. (Copy here)
(An expanded, edited and better version of this is available in our March 4, 2016 reply comment to USTR, available here: http://www.keionline.org/node/2440)
These were my notes from my testimony for KEI at today's USTR Special 301 hearing
Big market puts countries on the #special301 watch list
The dearth of recent compulsory licenses out of India has led to speculation that the Government has made an agreement not to issue such licenses.
On reviewing submissions for the Office of the United States Trade Representative's upcoming 2016 Special 301 Review, several industry documents confirm that such an agreement exists.
KEI is one of the non-government entities speaking at the USTR Special 301 hearing on Tuesday. We each get 7 minutes of testimony and 3 minutes of questions. (The schedule is here).